Robert Sandrock is a seasoned professional with over 20 years of experience in drug discovery and biotechnology. Currently serving as Clinical Omics Director at Amgen since May 2022, Robert utilizes omics insights to inform the development strategy of novel therapeutics. Previous roles include Director of Technology at Capsida Biotherapeutics and Chief Scientific Officer and Founder at Pharmony Consulting LLC. Earlier career highlights at Amgen involve leadership positions in the Biosimilars Business Unit and Genome Analysis Unit, where Robert contributed significantly to biosimilar programs and next-generation sequencing initiatives. Robert's background also includes research at ARUP Laboratories, Q Therapeutics, Genta, and Deltagen Proteomics, with a strong emphasis on assay development and cellular propagation methods in various biological contexts. Educational qualifications include a B.S. in Molecular Genetics from The Ohio State University, a Ph.D. in Plant Pathology from the University of Arizona, and post-doctoral research at Cornell University in Molecular Plant Pathology.
This person is not in any offices